NIOX, developed and distributed by Aerocrine/Stallergenes, is the first point-of-care medical device for measuring Fractional Exhaled Nitric Oxide (FeNO), according to guidelines for NO measurements established by the American Thoracic Society, thereby providing personalized asthma management. It enables clinicians to obtain an accurate, quantitative measure of airway inflammation to more effectively assess and manage asthma.
Measuring exhaled NO (a marker for inflammation) provides an immediate and complete clinical overview on:
NIOX is a portable, handheld device which is the only calibration and maintenance-free NO device, for effective asthma management.
NIOX is suitable for children approximately 7-17 years, and adults 18 years and older.
Genpharm has partnered with Stallergenes to commercialize NIOX in the U.A.E.
For more information on NIOX availability in the U.A.E, please contact us on: